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INTRODUCTION
In a variety of studies, chromosomal abnormalities
detected in bone marrow cytogenetic analysis at the time of
diagnosis have been shown to be key prognostic indicators
in acute myeloid leukemia (AML) [1-12]. In particular, the
response to standard induction and consolidation chemo-
therapy is heavily influenced by the specific karyotypic
abnormalities identified [1,8,12,13]. Several chromosomal
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ABSTRACT
Cytogenetic abnormalities detected at diagnosis are recognized as important in predicting response to chemo-
therapy in acute myeloid leukemia (AML). However, there is controversy concerning the prognostic significance of
karyotype for outcome after allogeneic bone marrow transplantation (allo-BMT) performed in first complete remis-
sion (CR1). This single-institution report describes allo-BMT for AML in CR1 and the effect of diagnostic cytoge-
netic findings on the results of that treatment. Between August 1981 and December 1999, 93 patients underwent
related donor (n = 82) or unrelated donor (n = 11) BMT. Conditioning and GVHD prophylaxis were achieved pre-
dominantly with busulfan and cyclophosphamide and with cyclosporine and methotrexate, respectively. Seventy-
nine (85%) of 93 patients had successful marrow karyotyping at diagnosis, and the patients were categorized into
3 prognostic groups based on the British Medical Research Council AML 10 trial classification: 15 patients (19%)
were classified as having favorable risk [inv(16), t(8;21), t(15;17)]; 55 (70%) as having intermediate risk [no abnor-
mality, +8, +21, +22, del(7q), del(9q), 11q23 rearrangement, and other numerical or structural abnormalities]; and
9 (11%) as having adverse risk [–5, del(5q), –7, 3q rearrangements, ≥5 abnormalities, t(6;9), t(9;22)]. The median
follow-up was 93 months (range, 16-241 months). The overall survival (OS) rate, event-free survival (EFS) rate,
relapse rate, and treatment-related mortality (TRM) were not statistically different between the groups. The 5-year
actuarial EFS rates for favorable, intermediate, and adverse risk groups were 58% (95% confidence interval [CI],
29%-79%), 58% (95% CI, 43%-70%), and 67% (95% CI 28%-88%), respectively. Reclassification of patients into
cytogenetic prognostic subgroups according to Southwest Oncology Group criteria did not change these results. In
univariate analysis, the only variable found to have a prognostic influence on OS (P = .04) and TRM (P = .03) was
the type of donor (unrelated donor was linked to a worse prognosis), which was confirmed in multivariate analysis.
Our study suggests that presentation karyotype has less prognostic significance for outcome following allo-BMT
than for outcome following conventional chemotherapy. In particular, AML patients with poor prognostic cytoge-
netic changes in CR1 who are unlikely to be cured with chemotherapy alone may benefit from allo-BMT.
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changes, ie, t(8;21), t(15;17), and inv(16), have consistently
predicted a relatively favorable outcome following chemo-
therapy, whereas others, eg, –5, –7, or complex karyotypic
changes, have been associated with a poor outcome. How-
ever, studies with large numbers of patients in which cytoge-
netic analysis was consistently and successfully performed
have only recently begun to clarify the prognostic signifi-
cance of other aberrant karyotypes and their variants in
AML [1,2]. The importance of cytogenetic analysis as a pre-
dictive variable in AML has been recognized by the World
Health Organization in their recent proposal for a revised
classiﬁcation of subtypes of this disorder [14]. The results of
cooperative group studies in which cytogenetic analysis was
included in multivariate analyses suggested that postremis-
sion therapy can reasonably be tailored to individual patients
based on the prognosis predicted by their diagnostic bone
marrow karyotype [1,2,8,15].
In contrast to the consistent predictive value that cyto-
genetic analysis has had for chemotherapy response and sur-
vival in AML, the prognostic value of chromosomal analysis
for patients in ﬁrst complete remission (CR1) who receive
allogeneic bone marrow transplantation (allo-BMT) as con-
solidation therapy is less clear. Some studies have demon-
strated a similar value for karyotypic studies in predicting
outcome after allo-BMT [16-18], whereas others have failed
to observe this effect [4,19-22]. Several of the larger studies
that suggested a prognostic value for chromosome abnor-
malities in this situation were cooperative group or registry
analyses in which the proportion of patients with evaluable
cytogenetic analysis was relatively small [17] or the treat-
ment protocols were variable [16-18]. On the other hand, in
cases in which no predictive value was seen, the number of
patients available for analysis was often small [4,20,21], or
the way in which the chromosomal changes were assigned to
various prognostic groups was different from what might
now be accepted [4,19,20].
As part of the analysis of the British Medical Research
Council (MRC) experience in the treatment of more than
1500 patients with AML, prognostic categories for cytoge-
netic abnormalities were recently published [1]. In this
report, the numbers of patients with specific karyotype
alterations associated with AML were sufficient for the
event-free survival (EFS) and overall survival (OS) rates
associated with individual abnormalities to be determined
with confidence and compared to each other. Three cate-
gories of chromosomal changes associated with a good,
intermediate, or poor prognosis were identiﬁed. The South-
west Oncology Group (SWOG) has adopted a somewhat
different prognostic categorization of cytogenetic abnormal-
ities for AML. Certain frequent cytogenetic abnormalities
judged as conferring an intermediate prognosis by the MRC
were considered by the SWOG to confer a poor risk, result-
ing in changes in category assignment for a substantial num-
ber of patients. In the current study, we have used both the
MRC and the SWOG classiﬁcations to evaluate retrospec-
tively the prognostic effect of diagnostic karyotype on the
outcome of 93 consecutive allo-BMTs performed in adults
with AML in CR1 at the Vancouver Hospital and Health
Sciences Center (VHHSC). In addition, the influence of
other known prognostic clinical variables was considered for
the 79 patients in whom cytogenetic analysis was successful.
MATERIALS AND METHODS
Patient Characteristics
Between November 1981 and December 1999, 93 patients
with de novo AML in CR1 underwent allogeneic BMT
(Table 1). Except in unusual circumstances, consolidation
chemotherapy was not given prior to BMT. All patients pro-
vided informed consent, and all research studies were
approved by the University and Institutional Review Boards.
Bone marrow histopathology was centrally reviewed at
VHHSC with diagnoses based on standard French-American-
British (FAB) criteria [23].
Cytogenetic Analysis
Cytogenetic analyses were performed on unstimulated
cultured marrow specimens at 4 regional laboratories and
reviewed at VHHSC. The karyotypes were assessed accord-
ing to the International System for (Human) Cytogenetic
Nomenclature (ISCN) 1995 criteria [24]. Patients were
divided into 3 prognostic subgroups according to cytoge-
netic category based on the MRC AML 10 trial [1]. The fol-
lowing criteria were used: favorable, t(8;21), t(15;17),
inv(16); intermediate, no abnormality, +8, +21, +22, del(7q),
del(9q), 11q23 rearrangement, and other numerical or struc-
tural abnormalities; and adverse, –5, del(5q), –7, 3q
rearrangements, complex (≥5 abnormalities). In the MRC
AML 10 trial, the presence of additional cytogenetic abnor-
malities did not modify the outcome of patients within the
favorable category, and therefore additional cytogenetic
abnormalities were not taken into account when classifying
patients in the favorable group. Eleven of 15 patients in the
favorable group had such additional changes (Table 2). The
same group of patients was also divided into the 4 cytoge-
netic prognostic subgroups adopted by the SWOG [15]:
favorable, inv(16)/t(16;16)/del(16q), t(15;17) with or without
secondary aberrations or t(8;21) lacking del(9q) or being
part of a complex karyotype; intermediate, normal, +8, +6,
–Y, del(12p); adverse, del(5q)/-5, –7/del(7q), abnormalities
of 3q, 9q, 11q, 20q, 21q, or 17p, t(6;9), t(9;22) and complex
Table 1. Patient Characteristics (n = 79)
Age, median (range), y 38 (17-55)
Sex, M/F 37/42
WBC, median (range), ×109/L 11.2 (0.8-252)
FAB classification, no. of patients
M0 3
M1 16
M2 13
M3 9
M4 21
M5 12
M6 2
Unclassifiable 3
No. of patients with 1 cycle of chemotherapy to 65 
enter CR1
No. of patients with >1 cycle of chemotherapy to 14 
enter CR1
Time from diagnosis to BMT, median (range), mo 3.3 (1.8-9.0)
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karyotypes (≥3 unrelated abnormalities); and unknown, all
other abnormalities. Thus, the major differences between
the 2 classiﬁcations are the deﬁnition of complex karyotype
(≥5 abnormalities in MRC versus ≥3 unrelated abnormali-
ties in SWOG); the classification of 11q abnormalities as
intermediate by MRC and adverse by SWOG; and the clas-
sification by MRC of all t(8;21) as favorable, despite the
presence of either del(9q) or complex karyotypes. In addi-
tion, all SWOG karyotypes of unknown prognostic signiﬁ-
cance are designated as intermediate risk by MRC criteria.
Conditioning Regimens
Details of the conditioning regimens are shown in Table 3.
A diagnostic lumbar puncture was performed at the begin-
ning of conditioning with intrathecal injection of cytosine
arabinoside 30 mg/m2 or methotrexate 12 mg. In general,
cyclophosphamide (Cy) with fractionated total body irradia-
tion (TBI) was used before unrelated donor BMT (Cy: 50
mg/kg intravenously [IV] daily, days –6 to –4; TBI: 200 cGy
twice a day, days –3 to –1), and a busulfan (Bu)-based regi-
men, primarily BuCy-2 [25], was used for related donor BMT
patients (Bu: 1 mg/kg by mouth every 6 hours daily, days –7
to –4; Cy: 60 mg/kg IV daily, days –3 and –2). Patients receiv-
ing Bu were given phenytoin as seizure prophylaxis [26].
Uroepithelial prophylaxis was with hyperhydration.
Bone Marrow Transplantation
Seventy patients received marrow from a histocompati-
ble sibling, 5 from a 1-antigen mismatched sibling, and 2 from
matched relatives. Three patients received peripheral blood
stem cells from a histocompatible sibling, 1 patient received
peripheral blood stem cells from a 1-antigen mismatched
sibling, and 1 patient received marrow and peripheral blood
from a sibling. Eleven patients received marrow from an
unrelated donor; 9 pairs were matched, 1 pair was 1-antigen
mismatched, and 1 pair was 2-antigen mismatched. Bone
marrow was plasma- and/or erythrocyte-depleted when
necessitated by ABO incompatibility [27].
Graft-versus-Host Disease Prophylaxis
Details of the different graft-versus-host disease
(GVHD) prophylaxis regimens used are outlined in Table 3.
The majority of patients received cyclosporine (CSP) and
short-course methotrexate with or without other agents
[28-31]. One patient received unrelated donor bone marrow
that was T-cell depleted by an immunomagnetic cell separa-
tion technique using iron-dextran particles cross-linked to
anti-CD3 antibodies [32]. Treatment of established acute
GVHD was with high-dose methylprednisolone (MP);
those with GVHD resistant to MP received an anti–T-cell
antibody, either anti-CD5/ricin immunotoxin (XomaZyme;
XOMA, Berkeley, CA) [29], interleukin-2 receptor anti-
body (BT563 or B-B10; Biotest, Dreieich, Germany), or
antithymocyte globulin (either ATGAM [Upjohn, Kalamazoo,
MI] or thymoglobulin [Sangstat Medical, Menlo Park, CA]).
GVHD was graded according to standard criteria [33].
Supportive Care
Patients were treated on the Leukemia and Bone Mar-
row Transplant Unit at the VHHSC in rooms equipped
Table 2. Cytogenetic Abnormalities and Prognostic Groups*
No. of Patients No. of Patients
MRC Classification (% of Total) SWOG Classification (% of Total)
Favorable 15 (19) Favorable 15 (19)
t(8;21) + additional changes 3 t(8;21) + additional changes 3
t(15;17) alone 3 t(15;17) alone 3
t(15;17) + additional changes 3 t(15;17) + additional changes 3
inv(16) alone 1 inv(16) alone 1
inv(16) + additional changes 5 inv(16) + additional changes 5
Intermediate 55 (70) Intermediate 40 (51)
Normal karyotype 36 Normal karyotype 36
+8 4 +8 4
+21 1
del(7q) 1
del(9q) 1
11q23 rearrangement 6
Other numerical or structural abnormalities 6
Adverse 9 (11) Adverse 18 (23)
3q rearrangement 5 3q rearrangement 5
Complex (≥5 unrelated abnormalities) 2 Complex (≥3 unrelated abnormalities) 3
t(6;9)† 1 t(6;9) 1
t(9;22)† 1 t(9;22) 1
11q23 rearrangement 6
del(7q) 1
del(9q) 1
Unknown or other 6 (7)
Total 79 Total 79
*As described in “Materials and Methods.”
†Risk status for t(6;9) or t(9;22) is not deﬁned by MRC criteria, possibly because of a lack of these low-frequency aberrations in their cohort.
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with high-efﬁciency particulate air (HEPA) ﬁltration. Hick-
man catheters were used routinely. Empiric IV antibiotics,
amphotericin B, acyclovir, cytomegalovirus (CMV)-negative
blood products, high-titer anti-CMV immunoglobulin, and
total parenteral nutrition were given as required. Low-dose
heparin (100 U/kg per day) for veno-occlusive disease pro-
phylaxis was given routinely after November 1992 [34].
From June 1992, fungal prophylaxis was with ﬂuconazole IV
at 200 to 400 mg per day or amphotericin B IV at 10 mg/m2
per day. From September 1992, if the donor or recipient was
CMV antibody positive, gancyclovir was given from
engraftment until day 100 at a dose of 5 mg/kg IV twice a
day for 5 days and then 5 mg/kg daily from Mondays to Fri-
days or as adjusted for renal impairment. Growth factors
were used for graft failure, drug-induced neutropenia, and,
from October 1995 to September 1997, in patients receiving
postengraftment gancyclovir as part of a separate study [35].
Statistical Analysis
The actuarial OS, EFS, treatment-related mortality
(TRM), and relapse probabilities were calculated using the
product limit estimates of Kaplan and Meier [36], with sur-
viving patients being censored on January 30, 2002. The fol-
lowing factors were analyzed with respect to OS, EFS,
TRM, and relapse rates: recipient age, white blood cell count
(WBC) at diagnosis, FAB classiﬁcation, cytogenetic prognos-
tic group (favorable, intermediate, or adverse according to
MRC criteria), number of chemotherapy cycles to enter CR1
(1 or >1 cycle), time from diagnosis to BMT, donor type
(related/unrelated), and year of BMT. Univariate and multi-
variate analyses of prognostic factors were performed using
Cox’s proportional hazard regression model [37].
RESULTS
Seventy-nine (85%) of 93 patients had successful marrow
karyotyping at diagnosis. In 3 patients, karyotyping was
attempted but no analyzable metaphases were obtained,
and in 11 patients, cytogenetic analysis was not performed
at diagnosis (patients were diagnosed and treated with
induction chemotherapy before referral to VHHSC for
BMT). Because there were no differences in OS, EFS, TRM,
or risk of relapse between the patients who had successful
marrow karyotyping and those who did not, the analysis
included only patients with available karyotype at diagnosis
(79 patients). The patients were divided into the 3 prognos-
tic karyotype groups according to MRC criteria as deﬁned in
“Materials and Methods”. Fifteen patients (19%) were in the
favorable-prognosis group, 55 patients (70%) were in the
intermediate-prognosis group, and 9 patients (11%) were in
the adverse-prognosis group (Table 2). In the favorable-
prognosis group, 11 of 15 patients had chromosomal abnor-
malities in addition to the favorable change. In 4 patients,
these abnormalities were numerical chromosomal abnormal-
ities commonly seen with such changes [–Y in 2 patients with
t(8;21) and +22 in 2 patients with inv(16)]. None of these
11 cases had poor prognostic karyotypic changes in associa-
tion with the good prognostic chromosomal abnormality. In
the intermediate-prognosis group, 36 of 55 patients had a
normal karyotype, which is 46% of the total group, a pro-
portion very similar to that reported by others [1,2,6]. The
adverse-prognosis group consisted of 9 patients, 5 of whom
had a 3q rearrangement and 2 of whom had complex cytoge-
netic changes, 1 patient a t(6;9) and another a t(9;22).
With a median follow-up of 93 months (range, 16-241
months), the 5-year OS rates were not statistically signiﬁ-
cantly different between the 3 cytogenetic risk groups: 65%
(95% conﬁdence interval [CI], 35%-84%) for the favorable-
prognosis group, 57% (95% CI, 42%-70%) for the interme-
diate group, and 67% (95% CI, 28%-8%) for the adverse
group (P = .76). There was also no difference in the 5-year
EFS rates among the 3 groups: 58% (95% CI, 29%-79%)
for the favorable-prognosis group, 58% (95% CI, 43%-
70%) for the intermediate group, and 67% (95% CI, 28%-
88%) for the adverse group (P = .90; Figure 1A). The TRM
rates were similar among the 3 groups: 14% (95% CI, 4%-
45%) in the favorable, 23% (95% CI, 12%-39%) in the
intermediate, and 0% in the adverse group (P = .37). The
5-year relapse rates were also not significantly different:
32% (95% CI, 13%-66%) in the favorable, 25% (95% CI,
15%-40%) in the intermediate, and 33% (95% CI, 12%-
72%) in the adverse risk group (P = .80; Figure 2A).
When the 79 patients were reclassiﬁed using the SWOG
criteria for cytogenetic prognostic subgroups, 9 patients’
cytogenetic changes that were coded as intermediate by
MRC criteria were assessed as adverse by SWOG criteria.
Consequently, the proportion of patients with adverse kary-
otype increased (24% for SWOG criteria compared to 11%
for MRC criteria). Six patients whose abnormalities were
coded as intermediate by MRC criteria had their abnormali-
ties categorized as unknown or other by the SWOG classiﬁ-
cation. Using the SWOG strategy, the 5-year OS rates were
65% (95% CI, 35%-84%) in the favorable group, 62%
(95% CI, 44%-76%) in the intermediate group, 54% (95%
CI, 29%-74%) in the adverse group, and 50% (95% CI,
11%-80%) in the unknown category (P = .69). EFS rates
were 58% (95% CI, 29%-79%) in the favorable group, 62%
(95% CI, 45%-76%) in the intermediate group, 56% (95%
CI, 31%-75%) in the adverse group, and 50% (95% CI,
11%-80%) in the unknown category (P = .82; Figure 1B).
The TRM rates were 14% (95% CI, 4%-45%) in the favor-
Table 3. Transplantation Details*
No. of Patients (% of Total)
Conditioning regimen
BuCy 63 (80)
Cy/TBI 11 (14)
AraC/Cy/TBI 3 (4)
Other 2 (2)
Stem cell source
Related donor 68 (86)
Unrelated donor 11 (14)
GVHD prophylaxis
CSP/MTX 56 (71)
CSP/MTX + other 13 (16)
CSP/MP 4 (5)
MTX and/or MP 3 (4)
Other 3 (4)
Unknown 0 (0)
*AraC indicates cytosine arabinoside; MTX, methotrexate.
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able group, 24% (95% CI, 13%-44%) in the intermediate
group, 11% (95% CI, 3%-38%) in the adverse group, and
0% in the unknown category (P = .60). Similarly, the 5-year
relapse rates were 32% (95% CI, 13%-66%) in the favor-
able group, 17% (95% CI, 8%-35%) in the intermediate
group, 38% (95% CI, 19%-65%) in the adverse group, and
50% (95% CI, 20%-89%) in the other group (P = .19; Fig-
ure 2B). Thus, the use of this alternative cytogenetic classiﬁ-
cation did not change the signiﬁcance of the different prog-
nostic subgroups after allo-BMT for AML in ﬁrst CR.
The different cytogenetic subgroups (by MRC criteria)
were also analyzed for the presence of other known prog-
nostic variables. Although patients in the favorable-prognosis
cytogenetic group were somewhat younger (67% were
<36 years old) than those in the intermediate-prognosis
(40%) and adverse-prognosis (44%) groups, the differences
in age did not reach statistical signiﬁcance (P = .24). More
patients with favorable cytogenetic changes had a low
WBC at diagnosis (66% of patients with WBC <109/L)
compared to patients in the intermediate group (45%) and
the adverse group (11%) (P = .018). Also, more patients in
the favorable- and intermediate-prognosis groups needed
only 1 cycle of induction chemotherapy to enter CR (93%
and 84%, respectively) than did patients in the adverse
group (56%) (P = .03). No patients in the favorable cytoge-
netic group and only 15% of patients in the intermediate
group received unrelated donor transplants compared to
33% of patients in the adverse group (P = .023). There were
no differences between the groups with respect to the time
from diagnosis to transplantation and the period when the
transplantation was done (ie, 1981-1991 versus 1992 or
later). The FAB subtypes of leukemias in the favorable-
prognosis group were M2, M3, or M4, whereas in the inter-
mediate group, all subtypes were represented and in the
adverse group, AML M0,M1,M4 and M5 were seen.
Univariate analysis of noncytogenetic variables for the
total group of 79 patients showed that only the use of unre-
lated donors had a prognostic inﬂuence on OS (P = .04) and
TRM (P = .03) and also had a trend toward reduced EFS
(P = .06). Unrelated donor transplants were also linked to a
worse prognosis than were related donor transplants in mul-
tivariate analysis for OS (P = .03) and TRM (P = .04). No
other variable was found to be a signiﬁcant predictor of OS,
EFS, TRM, or risk of relapse (Table 4).
DISCUSSION
This study analyzed the impact of diagnostic karyotype
on outcome following allo-BMT in patients with AML in
CR1 treated at a single institution. Although patient numbers
are small, the data demonstrate no difference in TRM rates,
relapse rates, disease-free survival (DFS) rates, or OS rates
among patients with cytogenetic changes known to predict
Figure 1. A, EFS after allo-BMT by cytogenetic prognostic group at
diagnosis using MRC criteria. B, EFS after allo-BMT by cytogenetic
prognostic group at diagnosis using SWOG criteria.
Figure 2. A, Risk of relapse after allo-BMT by cytogenetic prognostic
group at diagnosis using MRC criteria. B, Risk of relapse after allo-BMT
by cytogenetic prognostic group at diagnosis using SWOG criteria.
Y. Chalandon et al.
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different rates of successful remission induction, relapse, and
overall survival following conventional chemotherapy [1].
Fifteen percent of AML patients referred to our center
for allo-BMT during the period studied did not have cytoge-
netic analysis performed at diagnosis, reﬂecting the fact that
this investigation was not routinely available in all referring
centers before 1990. However, among those cases in which
karyotype analysis was performed, cytogenetic abnormalities
were detected in 52% overall, including failures and normal
results. This rate is similar to the frequencies reported in
large series of de novo AML patients [1,2,6].
Among the 15 patients with cytogenetic changes consis-
tent with a favorable prognosis, 11 had additional changes.
However, 2 large studies have found that such additional
chromosomal abnormalities do not affect prognosis [1,17].
Thus, these changes were ignored when assigning patients
to cytogenetic risk groups. The OS and DFS rates following
allo-BMT of this patient group in our series were very simi-
lar to those reported by the MRC group and others [1,17].
Currently, most centers, including our own, would not
perform transplantation for patients in the favorable cytoge-
netic prognostic group in CR1 because available data suggest
that this approach has no advantage over chemotherapy alone
[1,8]. However, the majority of the 15 favorable-prognosis
patients in our series received transplants before 1997, at
which time these facts were not fully appreciated.
Of our 9 patients with adverse prognostic cytogenetic
abnormalities, 7 were alive and free of disease 16 to 130 months
following transplantation. These data contrast with our
experience in patients receiving allografts for myelodysplas-
tic syndrome (MDS), among whom adverse cytogenetic
changes as deﬁned by the International Prognostic Scoring
System for MDS [38] predicted a substantially increased
relapse rate and shorter survival following allo-BMT than
seen in the standard- and good-risk cytogenetic subgroups
[39]. However, different classifications of cytogenetic risk
groups were used in the 2 studies, and the speciﬁc abnor-
malities seen in the patients included in the poor-prognosis
groups also differed. Among 17 MDS patients in the poor-
prognosis group, 7 patients had abnormalities of chromo-
some 7 and 10 patients had 3 or more chromosomal
changes. In the current series, 5 of 9 AML patients had
chromosome 3q rearrangement, with 1 of these patients
having 2 additional chromosomal changes.
Table 4. Univariate Analysis for Outcome at 5 Years 
OS EFS Relapse TRM
Characteristics No. of Patients % P % P % P % P
Age at diagnosis, y
17-25 17 52 52 41 12
26-35 19 72 .29 67 .33 22 .28 14 .63
36-55 43 57 58 25 23
WBC at diagnosis
0-9 × 109/L 36 58 55 29 23
10-50 × 109/L 28 59 .95 59 .88 26 .90 20 .60
>50 × 109/L 14 63 63 32 7
FAB classification*
M0 3 67 67 0 33
M1 16 43 44 46 19
M2 13 58 49 11 45
M3 9 67 .45 67 .37 25 .63 11 .14
M4 21 66 66 30 6
M5 12 64 64 25 14
M6 2 100 100 0 0
Karyotype (MRC criteria)
Favorable 15 65 58 32 14
Intermediate 55 57 .77 58 .90 25 .76 23 .37
Adverse 9 67 67 33 0
No. of cycles to enter CR
1 cycle 65 57 56 32 18
>1 cycle 14 71 .96 71 .81 9 .16 21 .17
Time from diagnosis to BMT
0-12 weeks 29 54 51 36 20
13-24 weeks 42 55 .24 55 .41 29 .40 23 .75
>24 weeks 8 100 100 0 0
Type of donor
Related 68 62 60 27 17
Unrelated 11 45 .04 45 .06 38 .56 27 .03
Year of BMT
1981-1991 28 64 64 23 16
>1991 51 58 .32 57 .30 30 .56 19 .35
*Unclassiﬁable in 3 patients.
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The poor-prognosis group of patients in the current
study was 11% of the total group of allo-BMT patients stud-
ied. Although this proportion is similar to the frequency
determined at diagnosis of AML in the MRC trial [1], it may
also reﬂect the low CR1 rate and short remission duration in
this group of patients. Thus, it is likely that some AML
patients with high-risk chromosomal abnormalities failed to
enter CR or relapsed before they could be referred to our
center to undergo allo-BMT. The biology of disease among
these 9 patients who received transplants was probably rela-
tively favorable compared to that generally observed in AML
patients in the unfavorable-prognosis karyotype group. Of
note, none of the patients studied here had –5, –7, or del(5q),
cytogenetic abnormalities that are known to be associated
with a particularly poor prognosis and whose frequency
increases in older patients in whom allo-BMT cannot be
considered [2,12]. The absence of such patients may have
had a favorable impact on the OS and DFS of the group with
adverse prognosis cytogenetic abnormalities in our series.
However, when we further analyzed the 3 cytogenetic sub-
groups for the frequency of other prognostic variables, we
found that among patients with adverse-prognosis cytoge-
netics compared to the other 2 groups there was a higher
percentage of patients who were older, had higher presenting
WBC counts, required more than 1 cycle of induction
chemotherapy to enter CR, and more often had an unrelated
donor as the stem cell source. These differences were statisti-
cally significant for the last 3 variables, demonstrating the
generally unfavorable characteristics of this patient group.
Nevertheless, these data indicate that long-term DFS is pos-
sible after allo-BMT for some patients in the poor-prognosis
group if transplantation is carried out in CR1.
Our ﬁnding that there was no correlation between the
cytogenetic prognostic risk group assigned at diagnosis in
AML patients and OS, EFS, or TRM is consistent with sev-
eral European studies in which the number of patients stud-
ied was similar [4,20,21]. Interestingly, 2 of these series
[4,20] used the same classification of karyotype abnormali-
ties as did Keating et al. [19] in a substantially larger study
in which cytogenetic abnormalities showed a trend toward
prediction of relapse rate after allo-BMT. The major dif-
ference between this classification and the MRC classifica-
tion is that in the former classification, the intermediate-
prognosis group included normal karyotype and –Y only,
with all other abnormalities (other than the 3 recognized
good prognostic changes) included in the poor-prognosis
group [19]. The more recent MRC study has reclassiﬁed a
number of common abnormalities from the poor- to the
intermediate-prognosis group, ie, +8, 11q23 rearrangement,
+21, del(7q), +22, and other numerical and structural abnor-
malities that did not meet their criteria for adverse prognos-
tic significance [1]. This difference might explain why the
former studies observed less difference between the poor-
and intermediate-prognosis subgroups than did the latter
study. In addition to the MRC study, 2 other large coopera-
tive group reports and an International Bone Marrow
Transplant Registry (IBMTR) analysis have demonstrated a
prognostic signiﬁcance for karyotype on outcome after allo-
BMT [16-18]. In each case, the cytogenetic risk-group clas-
siﬁcation was different from that of the MRC, with 11q23
rearrangements and del(7q) notably classiﬁed with the poor-
risk group and complex abnormalities that did not involve –5
or –7 [16] or t(9;22) [17,18] classiﬁed with the intermediate-
risk group. Although no specific mention is made of 3q
rearrangements in these 3 studies, it appears that they would
have been classiﬁed with the intermediate-risk group in 2 of
the 3 studies [16,17]. Five of our 9 poor-prognosis patients
had 3q rearrangements, and as of this report 4 of them were
alive and free of disease after allo-BMT, suggesting that
AML with 3q rearrangements may be more effectively
treated with allo-BMT than are leukemias with other poor
prognostic changes. Because the MRC study did not indi-
cate how many of their allo-BMT patients carried the 3q
rearrangement, a direct comparison of their poor-risk trans-
plantation patients and ours cannot be made. To determine
if our choice of the MRC cytogenetic classification had
influenced our results, we reclassified the patients accord-
ing to SWOG cytogenetic criteria. Although the SWOG
reclassification increased the number of patients in the
poor-prognosis category in our series, it had no impact on
our ﬁnding that there was no signiﬁcant difference in OS,
DFS, relapse rate, and TRM between the different prognos-
tic subgroups.
The primary aim of this study was to examine the rela-
tionship between karyotype and outcome after allo-BMT.
However, we also evaluated the effects of other factors that
have been shown to influence response to treatment and
survival in AML, ie, age at diagnosis, WBC count at diagno-
sis, FAB classification, number of chemotherapy cycles to
enter CR, time from diagnosis to BMT, the use of related or
unrelated donors, and year of transplantation [8,19,40-42].
The only variable found to have an impact on OS and TRM
was the use of an unrelated donor, which was associated with
a worse prognosis.
In summary, although the small size of this study limits
its power to identify subtle differences between prognostic
groups, the data suggest that the diagnostic karyotype had a
relatively minor impact on outcome after allo-BMT for
AML in CR1. It is encouraging that long-term DFS is at
least a possibility for patients with a poor prognostic kary-
otype. These results are consistent with those recently pub-
lished by the SWOG/Eastern Cooperative Oncology Group
(ECOG), in which AML patients with unfavorable cytoge-
netics who received allo-BMT obtained a signiﬁcant survival
advantage over those receiving an autologous transplant or
conventional chemotherapy [15]. More recently, the Euro-
pean Organization for Research and Treatment of Cancer–
Gruppo Italiano Malattie Ematologiche dell’Adulto
(EORTC-GIMEMA) AML-10 trial, which included a larger
number of patients in the poor-risk category than did the
MRC trial and most other studies, demonstrated that
patients with poor prognostic cytogenetics who proceeded
to allo-BMT had a similar outcome to those in other prog-
nostic subgroups and a significantly improved outcome
compared to patients with poor prognostic cytogenetics in
whom allo-BMT was not performed [22].
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